<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Multimodal Deep Learning for Prediction of Progression-Free Survival in Patients with Neuroendocrine Tumors Undergoing 177Lu-based Peptide Receptor Radionuclide Therapy - Health AI Hub</title>
    <meta name="description" content="This study developed and evaluated unimodal and multimodal deep learning models for predicting progression-free survival (PFS) in 116 patients with metastatic n">
    <link rel="icon" type="image/svg+xml" href="../favicon.svg">
    <link rel="icon" type="image/png" sizes="32x32" href="../favicon-32x32.png">
    <link rel="icon" type="image/png" sizes="16x16" href="../favicon-16x16.png">
    <link rel="stylesheet" href="../styles.css">
</head>
<body>
    <header>
        <div class="container">
            <div class="breadcrumb">
                <a href="../index.html">‚Üê Back to all papers</a>
                <a href="../index.html" class="home-btn">üè† Home</a>
            </div>
        </div>
    </header>

    <main class="container paper-detail">
        <article>
            <h1>Multimodal Deep Learning for Prediction of Progression-Free Survival in Patients with Neuroendocrine Tumors Undergoing 177Lu-based Peptide Receptor Radionuclide Therapy</h1>

            <div class="paper-metadata">
                <div class="meta-row">
                    <strong>arXiv ID:</strong> <a href="http://arxiv.org/abs/2511.05169v1" target="_blank">2511.05169v1</a>
                </div>
                <div class="meta-row">
                    <strong>Published:</strong> 2025-11-07
                </div>
                <div class="meta-row">
                    <strong>Authors:</strong> Simon Baur, Tristan Ruhwedel, Ekin B√∂ke, Zuzanna Kobus, Gergana Lishkova, Christoph Wetz, Holger Amthauer, Christoph Roderburg, Frank Tacke, Julian M. Rogasch, Wojciech Samek, Henning Jann, Jackie Ma, Johannes Eschrich
                </div>
                <div class="meta-row">
                    <strong>Categories:</strong> cs.LG
                </div>
                <div class="meta-row">
                    <strong>Relevance Score:</strong> 1.00 / 1.00
                </div>
            </div>

            <div class="action-buttons">
                <a href="http://arxiv.org/abs/2511.05169v1" target="_blank" class="btn btn-primary">View on arXiv</a>
                <a href="http://arxiv.org/pdf/2511.05169v1" target="_blank" class="btn btn-primary">Download PDF</a>
            </div>

            <section class="paper-section">
                <h2>Summary</h2>
                <p class="summary-text">This study developed and evaluated unimodal and multimodal deep learning models for predicting progression-free survival (PFS) in 116 patients with metastatic neuroendocrine tumors (NETs) treated with 177Lu-DOTATOC PRRT. The research found that a multimodal fusion model, combining laboratory values, pre-therapeutic SR-PET, and CT imaging, significantly outperformed unimodal approaches, achieving an AUROC of 0.72 for classifying short vs. long PFS.</p>
            </section>

            <section class="paper-section">
                <h2>Medical Relevance</h2>
                <p>Accurate prediction of progression-free survival after peptide receptor radionuclide therapy (PRRT) for neuroendocrine tumors is critical for personalizing treatment strategies and optimizing patient management. This study's multimodal deep learning approach offers a significant advancement in identifying patients at higher risk of early progression, enabling more tailored therapeutic decisions and follow-up plans, thereby moving towards precision oncology.</p>
            </section>

            
            <section class="paper-section">
                <h2>AI Health Application</h2>
                <p>The paper details the application of multimodal deep learning models to predict progression-free survival in cancer patients (neuroendocrine tumors). This AI application aims to provide a prognostic tool for clinicians, enabling more individualized treatment planning and risk stratification for patients undergoing peptide receptor radionuclide therapy.</p>
            </section>
            

            <section class="paper-section">
                <h2>Key Points</h2>
                <ul class="key-points">
                    
                    <li>The study retrospectively analyzed 116 patients with metastatic NETs undergoing 177Lu-DOTATOC PRRT to predict progression-free survival (PFS).</li>
                    
                    <li>Data included clinical characteristics, baseline laboratory values, and pre-therapeutic somatostatin receptor PET/CT (SR-PET/CT) scans.</li>
                    
                    <li>Seven models were developed for binary classification of low-PFS (<1 year, 36% of patients) vs. high-PFS (>1 year), including unimodal (laboratory Random Forest, 3D CNNs for SR-PET and CT) and multimodal deep learning fusion approaches.</li>
                    
                    <li>Unimodal models showed modest performance: a Random Forest model on laboratory biomarkers achieved an AUROC of 0.59 ¬± 0.02, while 3D CNNs on SR-PET and CT images performed worse (AUROC 0.42 ¬± 0.03 and 0.54 ¬± 0.01, respectively).</li>
                    
                    <li>The best performance was achieved by a multimodal deep learning fusion model combining laboratory values, SR-PET, and CT (augmented with a pretrained CT branch), yielding an AUROC of 0.72 ¬± 0.01 and AUPRC of 0.80 ¬± 0.01.</li>
                    
                    <li>Patients with shorter PFS exhibited statistically significant differences in baseline characteristics, including higher chromogranin A (p=0.003), elevated gamma-GT (p=0.002), and fewer PRRT cycles (p<0.001) compared to those with longer PFS.</li>
                    
                    <li>The findings demonstrate that integrating diverse data types through multimodal deep learning can significantly improve PFS prediction in PRRT patients, potentially enabling individualized treatment planning and risk-adapted follow-up.</li>
                    
                </ul>
            </section>

            <div class="two-column">
                <section class="paper-section">
                    <h2>Methodology</h2>
                    <p>This was a retrospective, single-center study involving 116 patients with metastatic neuroendocrine tumors (NETs) treated with 177Lu-DOTATOC. Data collected included clinical characteristics, baseline laboratory values (e.g., chromogranin A, gamma-GT), and pre-therapeutic somatostatin receptor PET/CT (SR-PET/CT) images. Seven distinct models were trained for binary classification of low-PFS (<1 year) vs. high-PFS (>1 year). These included unimodal approaches (Random Forest for laboratory data, 3D Convolutional Neural Networks for SR-PET and CT images) and multimodal deep learning fusion models. The most successful multimodal model integrated laboratory values, SR-PET, and CT, further augmented with a pretrained CT branch. Model explainability was assessed via feature importance analysis and gradient maps.</p>
                </section>

                <section class="paper-section">
                    <h2>Key Findings</h2>
                    <p>The multimodal deep learning fusion model, incorporating laboratory values, SR-PET, and CT imaging (augmented with a pretrained CT branch), achieved the best predictive performance with an AUROC of 0.72 ¬± 0.01 and an AUPRC of 0.80 ¬± 0.01. This performance significantly surpassed all unimodal models: the Random Forest on laboratory biomarkers (AUROC 0.59 ¬± 0.02), the 3D CNN on SR-PET (AUROC 0.42 ¬± 0.03), and the 3D CNN on CT (AUROC 0.54 ¬± 0.01). Furthermore, baseline analysis revealed that patients with shorter PFS had significantly higher baseline chromogranin A (p = 0.003), elevated gamma-GT (p = 0.002), and fewer PRRT cycles (p < 0.001).</p>
                </section>
            </div>

            <section class="paper-section">
                <h2>Clinical Impact</h2>
                <p>The development of a robust multimodal deep learning model for PFS prediction has the potential to profoundly impact clinical decision-making for NET patients undergoing PRRT. By accurately identifying patients at high risk of early progression, clinicians can tailor individualized treatment plans, consider more aggressive or alternative therapies, or implement risk-adapted follow-up strategies. This could optimize patient outcomes, reduce unnecessary procedures for low-risk patients, and improve resource allocation within healthcare systems.</p>
            </section>

            
            <section class="paper-section">
                <h2>Limitations</h2>
                <p>The study was retrospective and conducted at a single academic center, which inherently limits the generalizability of the findings to a broader, more diverse patient population. The cohort size of 116 patients, while suitable for initial model development, is relatively small for deep learning applications. Importantly, the reported model performance is based on internal validation, implying a need for external validation on independent datasets to confirm robustness and generalizability before clinical implementation.</p>
            </section>
            

            
            <section class="paper-section">
                <h2>Future Directions</h2>
                <p>The authors explicitly highlight the need for external validation of these multimodal deep learning models on larger, independent datasets. Successful external validation would be crucial for solidifying their clinical utility and paving the way for their integration into routine clinical practice to support risk-adapted follow-up strategies for NET patients post-PRRT.</p>
            </section>
            

            <section class="paper-section">
                <h2>Medical Domains</h2>
                <div class="tags">
                    
                    <span class="tag">Oncology</span>
                    
                    <span class="tag">Nuclear Medicine</span>
                    
                    <span class="tag">Radiology</span>
                    
                    <span class="tag">Medical Imaging</span>
                    
                    <span class="tag">Artificial Intelligence in Medicine</span>
                    
                    <span class="tag">Endocrinology</span>
                    
                </div>
            </section>

            <section class="paper-section">
                <h2>Keywords</h2>
                <div class="tags">
                    
                    <span class="tag tag-keyword">Neuroendocrine Tumors</span>
                    
                    <span class="tag tag-keyword">PRRT</span>
                    
                    <span class="tag tag-keyword">177Lu-DOTATOC</span>
                    
                    <span class="tag tag-keyword">Progression-Free Survival</span>
                    
                    <span class="tag tag-keyword">Deep Learning</span>
                    
                    <span class="tag tag-keyword">Multimodal Fusion</span>
                    
                    <span class="tag tag-keyword">SR-PET/CT</span>
                    
                    <span class="tag tag-keyword">Biomarkers</span>
                    
                </div>
            </section>

            <section class="paper-section">
                <h2>Abstract</h2>
                <p class="abstract">Peptide receptor radionuclide therapy (PRRT) is an established treatment for
metastatic neuroendocrine tumors (NETs), yet long-term disease control occurs
only in a subset of patients. Predicting progression-free survival (PFS) could
support individualized treatment planning. This study evaluates laboratory,
imaging, and multimodal deep learning models for PFS prediction in PRRT-treated
patients. In this retrospective, single-center study 116 patients with
metastatic NETs undergoing 177Lu-DOTATOC were included. Clinical
characteristics, laboratory values, and pretherapeutic somatostatin receptor
positron emission tomography/computed tomographies (SR-PET/CT) were collected.
Seven models were trained to classify low- vs. high-PFS groups, including
unimodal (laboratory, SR-PET, or CT) and multimodal fusion approaches.
Explainability was evaluated by feature importance analysis and gradient maps.
Forty-two patients (36%) had short PFS (< 1 year), 74 patients long PFS (>1
year). Groups were similar in most characteristics, except for higher baseline
chromogranin A (p = 0.003), elevated gamma-GT (p = 0.002), and fewer PRRT
cycles (p < 0.001) in short-PFS patients. The Random Forest model trained only
on laboratory biomarkers reached an AUROC of 0.59 +- 0.02. Unimodal
three-dimensional convolutional neural networks using SR-PET or CT performed
worse (AUROC 0.42 +- 0.03 and 0.54 +- 0.01, respectively). A multimodal fusion
model laboratory values, SR-PET, and CT -augmented with a pretrained CT branch
- achieved the best results (AUROC 0.72 +- 0.01, AUPRC 0.80 +- 0.01).
Multimodal deep learning combining SR-PET, CT, and laboratory biomarkers
outperformed unimodal approaches for PFS prediction after PRRT. Upon external
validation, such models may support risk-adapted follow-up strategies.</p>
            </section>

            

            
        </article>
    </main>

    <footer class="container">
        <p><a href="../index.html">‚Üê Back to all papers</a></p>
    </footer>
</body>
</html>